Item 8.01. Other Events.
On January 9, 2023, Kala Pharmaceuticals, Inc. (the "Company") received a letter
from the Listing Qualifications Department of The Nasdaq Stock Market LLC
("Nasdaq") notifying the Company that its application to transfer the listing of
its common stock, par value $0.001 per share (the "Common Stock"), from The
Nasdaq Global Select Market to The Nasdaq Capital Market had been approved. The
Nasdaq Capital Market is a continuous trading market that operates in
substantially the same manner as The Nasdaq Global Select Market and listed
companies must meet certain financial requirements and comply with Nasdaq's
corporate governance requirements. The transfer will be effective at the opening
of business on January 11, 2023. The Company's Common Stock will continue to
trade under the symbol "KALA."
The transfer was approved following Nasdaq's determination that the Company met
the applicable requirements for continued listing on The Nasdaq Capital Market,
including Listing Rule 5550(b)(1), the minimum stockholders equity requirement
for continued listing on The Nasdaq Capital Market. In addition, Nasdaq advised
the Company that, upon the transfer of its listing to The Nasdaq Capital Market,
the Company will also be in compliance with Nasdaq Rule 5550(a)(5), the market
value of publicly held shares requirement for continued listing on The Nasdaq
Capital Market.
© Edgar Online, source Glimpses
KALA BIO, INC. 
